

Index

A

Absence seizures, 9
Activated astrocytes, 4
ALDH7A1, 31
Alzheimer's disease, 43
Amygdala, 18
Anatomical basis, 15
Anesthetics, 60
Angelman syndrome, 45
Antiepileptic drugs, 9, 79
Antiseizure medications, 56
Aquaporin 4 channels, 3
Attention-deficit hyperactivity disorder, 42
Autism spectrum disorder, 42
Autoimmune epilepsy, 8
Autosomal dominant lateral temporal lobe epilepsy, 5, 19

B

Barbiturates, 9, 60
Bench to bedside, 28
Benzodiazepines, 9
Brivaracetam, 62

C

CA1, 3, 17, 18
CA3, 3, 18
CA4, 3

Carbamazepine, 9
Cation-chloride co-transporters, 4
Cenobamate, 9
Cerebellum and epilepsy, 20
Challenges in genetic evaluations, 33
Childhood epilepsy disorder, 120
Childhood onset epilepsy, 26, 29
Chromosomal abnormalities, 44
Chromosome 15q11-q13 duplication syndrome, 45
Classical hippocampal sclerosis, 18
Clinical practice, 25
Clinical studies, 41
Combined focal and generalized epilepsy, 42
Copy number variations, 44
Corpus callosotomies, 9
Cow's milk allergy, 124
Cryo-EM Structure, 82

D

Deep brain stimulation, 10
Dendritic pathology and epilepsy, 20
Dentate gyrus, 18
Dentate hilus, 3
Differential diagnoses, 2
Dormant basket cell theory, 18
Down syndrome, 27, 44
Dravet syndrome, 5
Drug-resistant epilepsy, 10

E

Early-stage status epilepticus, 57
Electrical stimulation, 68
Electroconvulsive therapy, 68
Electroencephalogram abnormalities, 43
End-folium, 18
ENGI, 26
Epi25 collaborative, 28
Epidemiology, 27
Epilepsy and neurodevelopmental disorders, 41
Epilepsy genes, 4
Epilepsy genetics, 25
Epilepsy Neurogenetics Initiative, 36
Epilepsy syndrome, 2, 42
Epilepsy, 1, 16
Epilepsy-associated variants of GABA_A, 99
Epilepsy-related cognitive dysfunction, 17
Epilepsy-related genes, 4
Epileptic encephalopathy, 4
Epileptic seizure, 2
Established status epilepticus, 58
Ethosuximide, 9
Etiology, 2
EuroEPINOMICS consortium, 28
Evaluation pathway, 31
Everolimus, 31
Excitatory mossy cells, 3
Extrahippocampal epilepsy, 19
Ezogabine, 9

F

Familial mesial temporal lobe epilepsy, 5
Familial variant testing, 34
Febrile seizures, 5, 27
Felbamate, 9
Focal epilepsy, 4, 16, 17, 42

Fos-PHT, 59
Fragile X syndrome, 46
Frontal cortex and epilepsy, 19

G

GABA reuptake inhibition, 9
GABA, 3
GABA_A receptor variants, 95
Gabapentin, 9
GABRG2, 27
Generalized epilepsy, 4, 16, 17, 42
Genetic analysis, 5
Genetic diagnoses, 28
Genetic epilepsies, 26
Genetic etiology, 4
Genetic studies, 41
Gliosis, 3, 17
Gut-brain axis, 120

H

HCN1, 27
Hemispherectomy, 9
Heritability, 35
Hippocampal sclerosis, 3, 4, 17, 18
Hippocampus and epilepsy, 16
Hyperexcitability, 16
Hypersynchronous neuronal discharge, 16
Hypersynchrony, 16
Hypothermia, 67

I

ILAE classification, 3
Immune etiology, 7
Immunotherapy, 65
In silico modeling/predictions, 35

Infectious etiology, 6
Inhalation anesthetics, 67
International League Against Epilepsy,
 1, 16, 42
Interpretation of results, 33

J

Juvenile myoclonic epilepsy, 4, 20

K

KCNQ2-related epilepsies, 27
Ketamine, 63
Ketogenic diet, 67, 119

L

Lacosamide, 9, 62
Lamotrigine, 9
Lateral neocortical epilepsy, 19
Levetiracetam, 58
Ligand-gated ion channels, 80
Lobectomy, 9
Lorazepam, 60

M

Magnesium infusion, 66
Magnetic stimulation, 68
MECP2-related disorders, 47
MEF2C-related disorders, 47
Mesial temporal lobe epilepsy, 17, 18
Metabolic epilepsy, 42
Midazolam, 60
Milk nutrition, 119
Models of overlap, 48
Modern treatment, 55
Molecular testing, 28
Mossy fiber sprouting, 3, 18

MRI, 4
Mutant $\alpha 4\beta 2$ AChRs, 6

N

Na-dependent action potentials, 9
Nav1.7 channel, 6
Neocortical temporal lobe epilepsy, 18
Neurobiological basis, 49
Neurodevelopmental disorders, 41
Neurodevelopment-associated
 epilepsy genes, 4
Neuronal cell loss, 17
Neuronal network synchronization, 4
Neuropeptidergic hilar, 3
Neurosteroids, 65
Neurostimulation, 10
Neurosurgical treatment, 9
Newer antiseizure medications, 62
Non-antiseizure medications, 63
Non-epileptic seizure, 16
Nonlesional epilepsy, 19
Novel targets, 79

O

Olfactory cortex and epilepsy, 19
Operational dimensions, 57
Oxcarbazepine, 62

P

Paradigm shift, 29
Parahippocampal gyrus, 18
Paroxysmal alteration, 16
Pathophysiological mechanisms, 1
Pathophysiology, 18
Patient care, 30
Pentobarbital, 60

Perampanel, 9, 62
Pharmacological treatment, 9
Phenobarbital, 59
Phenotypic heterogeneity, 30
Phenytoin, 9, 60
Potassium channels, 9
Prader-Willi syndrome, 45
Pregabalin, 62
Prevalence, 2
Propofol, 60
Pyramidal neurons, 3
Pyridoxine-dependent epilepsy, 31

Q

Quality of life, 10
Quality of testing, 33
Quaternary care facilities, 33
Quaternary level care, 32

R

Refractory status epilepticus, 60

S

SCN1A mutations, 27
SCN1B, 27
SCN9A, 27
Seizure semiology, 16
Seizure spread, 18
Seizures, 1
Selecting a laboratory and test, 33
Single gene diseases, 45
Status epilepticus, 55
Stiripentol, 62
Structural etiology, 2
Structure of GABA_A receptors, 96
Super-refractory status epilepticus, 61

Synaptic reorganization, 3
Synchronous neuronal activity, 2

T

Task force recommendations, 32
Temporal lobe and epilepsy, 18
Test interpretation, 33
Thalamus and epilepsy, 18
Theories of epilepsy, 18
Tiagabine, 9
Tonic depolarization, 18
Topiramate, 9, 62
Total hippocampal sclerosis, 18
Transient receptor potential channels, 79
Treatment options, 66
Treatment, 55
Trisomy 21, 44
TRPC, 80
TSC1, 27
TSC2, 27
T-type Ca²⁺ channels, 9
Tuberous sclerosis 27, 46

U

Uncus, 18
Unknown epilepsy, 42

V

Vagus nerve stimulator, 10
Valproate, 58
Valproic acid, 9
Variant frequency in population
database, 35
Voltage sensing-like domain, 82
Voltage-gated Ca²⁺ channels, 9
Voltage-gated ion channels, 80

W

White matter, 19

Whole genome sequencing, 32

Wild-type, 6

Worldwide, 2, 27

X

X chromosome-linked mental retardation
syndrome, 46

Xenopus oocytes, 5, 6

X-linked and autosomal recessive
inheritance, 30

Y

Yogurt and fermented milk, 121

Z

Zinc binding sites, 98

Zinc insensitive features, 98

Zinc sensitivity, 98

Zonisamide, 9

Doi: <https://doi.org/10.36255/exon-publications-epilepsy.index>

